Analytical Framework for Examining the Value of Antibacterial Products. 4.2.2 Pre-Clinical, Clinical Phase, and BLA Submission Costs

04/15/2014

We estimated per-phase costs for vaccine development using out-of-pocket pre-clinical and clinical period costs per investigational biopharmaceutical compound from DiMasi & Grabowski (2006).  These estimates were given in 2005 dollars; therefore, we inflated them using a consumer price index for medical care from BLS.  This resulted in cost totals of $73.9 million, $39.8 million, $46.5 million, and $118.6 million for the pre-clinical phase, Phase 1 trials, Phase 2 trials, and Phase 3 trials, respectively.

The reported new drug application fee for those drug or biologic product applications requiring clinical data is $1,958,800 for fiscal year 2013.  Thus, we use this figure as the BLA submission cost in the model as we did for antibacterial drug products.

View full report

Preview
Download

"rpt_antibacterials.pdf" (pdf, 1.43Mb)

Note: Documents in PDF format require the Adobe Acrobat Reader®. If you experience problems with PDF documents, please download the latest version of the Reader®